Metronomic Therapy Shows Promise in Breast Cancer

TOPLINE: Metronomic capecitabine combined with an aromatase inhibitor extends median progression-free survival to 20.9 months compared with 11.9 months for aromatase inhibitor alone in hormone receptor–positive breast cancer. The combination therapy demonstrates improved overall survival with tolerable safety profile, showing grade 3 adverse events in 15.1% of patients…
Read More